Followers | 831 |
Posts | 120096 |
Boards Moderated | 16 |
Alias Born | 09/05/2002 |
![](https://investorshub.advfn.com/uicon/14742.png?cb=1465058685)
Wednesday, January 09, 2008 1:10:31 AM
[Added detail on design of phase-2 IDX899
study and data to be reported at CROI.]
HIV
--Complete phase-2a IDX899 7-day monotherapy study (in progress); report interim results this study and complete results from phase-1b study at CROI conference in February. Also at CROI: results of phase-2 drug-interaction study with IDX899 and protease inhibitors.
--Start phase-2 IDX899 6-week combination study; this will be a head-to-head trial of IDX899+Truvada vs Sustiva+Truvada in first- or second-line patients.
--Partner IDX899 program following phase-2 study.
HCV
--File IND for the nucleotide prodrug, IDX184, and complete phase-1 trial.
--Start phase-2a study for IDX184 in combination with HCV SoC.
--File IND for HCV protease inhibitor and complete phase-1 trial.
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM
Kona Gold Beverages Reaches Out to Largest Debt Holder for Debt Purchase Negotiation • KGKG • Jul 17, 2024 9:00 AM
Avant Technologies Welcomes Back Former CEO with Eye Toward Future Growth and Expansion • AVAI • Jul 17, 2024 8:00 AM